Compare US Global Jets ETF (JETS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Natera Inc. Common Stock — how do they compare? US Global Jets ETF trades at $25.81 (market cap $812.53M), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 70.2× US Global Jets ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and Natera Inc. Common Stock for 0 Days on average.
| JETS | NTRA | |
|---|---|---|
Market Cap | $812.53M | $57.03B |
Volume | 5,144,947 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $425.64 |
52-Week Low | $23.64 | $179.42 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS is trading at $26.80, down 0.81% with a bearish technical outlook indicated by moving averages. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though strong travel demand provides some support. Recent news highlights underperformance compared to aerospace/defense ETFs, with fuel expenses surging 85% in May 2026 according to Reuters.
The outlook remains cautious due to fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term performance depends on fuel cost management and travel demand sustainability, with technical support at $26 providing a key level to watch.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
